Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
SURF302 interim results for intermediate-risk NMIBC show oral dabogratinib 60 mg with 79% ORR and 64% CR, described as well-tolerated for chronic dosing. The 60 mg dose is advancing to Phase III.
SURF302 initial results for oral dabogratinib 60 mg in intermediate-risk NMIBC report 79% ORR and 64% CR, with favorable safety, especially in single marker lesion patients, advancing to Phase III.